$17.00
-2.59-13.22%
Pelthos Therapeutics Inc (PTHS) Stock Price, Quote, News & History
PTHSAMEX
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
You can purchase shares of Pelthos Therapeutics (AMEX:PTHS) through any online brokerage.
Other companies in Pelthos Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Pelthos Therapeutics has a consensus price target of $52.83.
The stock price for Pelthos Therapeutics (AMEX: PTHS) is $20.29 last updated December 31, 1969 at 7:00 PM EST.
There are no upcoming dividends for Pelthos Therapeutics.
Pelthos Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Pelthos Therapeutics.
Pelthos Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA)...
